BridgeBio Pharma Launches CoA Therapeutics to Target Coenzyme-A for Rare Genetic Disorders

PALO ALTO, Calif., June 13, 2018 -- (Healthcare Sales & Marketing Network) -- BridgeBio Pharma today announced the launch of CoA Therapeutics, a biopharmaceutical company developing novel small-molecules designed to increase Coenzyme-A (CoA) levels in gen... Biopharmaceuticals BridgeBio Pharma, CoA Therapeutics, Coenzyme-A, PKAN
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news